HC Wainwright Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note released on Thursday, Benzinga reports. HC Wainwright currently has a $45.00 price objective on the stock.

A number of other research analysts have also recently commented on the company. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price target for the company. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Lifesci Capital started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target for the company. Wedbush started coverage on Oruka Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, TD Cowen started coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating on the stock. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics has a consensus rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Trading Down 2.9 %

Shares of NASDAQ ORKA opened at $27.19 on Thursday. The firm has a market cap of $32.90 million, a price-to-earnings ratio of -4.53 and a beta of 0.87. The firm has a fifty day moving average price of $26.86. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($25.92) earnings per share (EPS) for the quarter. As a group, research analysts expect that Oruka Therapeutics will post -1.69 EPS for the current year.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.